CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb's zola-cel, GSK's Be…
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb's zola-cel, GSK's Be…
Accomplished health care leader brings decades of experience in systems transformation, patient and family engagement, …
New NASM data reveals 73% of personal trainers are fielding client inquiries regarding GLP-1 therapies; updated course …
The analysis explores how AI-driven innovations are transforming skin disease detection, treatment planning and aesthet…
Stop & Shop Kicks Off Summer Grilling with Buy One, Get One Free Father’s Day Deal on Grass-Fed Steak
The next webinar in the 2026 Knock Out Opioid Abuse Day Learning Series will focus on the changing impact of the opioid…
According to MarketsandMarkets, the global poultry processing equipment market is estimated at USD 4.97 billion in 2026…
Thanks to the support of the Linda and Mike Mussallem Foundation, Octane has launched the Octane Mussallem Cardiovascul…
Lost Lantern introduces the United States of Bourbon, the first blend of bourbon from all 50 states, including a specia…
NeOnc(NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator Where the growth is going For i…
Dextreme 2.0 combines patented Error Augmentation technology, adaptive AI and immersive therapy to accelerate motor rec…
Study evaluates VCFix® used with or without bone cement, expanding clinical experience with the company’s minimally inv…